Odulimomab

Odulimomab (anti-LFA1) is an anti-LFA-1 monoclonal antibody. Odulimomab inhibits proliferation of T lymphocyte and shows protective effects against ischemia and reperfusion injury. Odulimomab can be used for the research of transplant rejection and immunological disease[1][2].

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Cytoskeleton >> Integrin

Odulimomab 在体外抑制 T 淋巴细胞增殖，以及 T 和自然杀伤细胞 (NK) 的细胞毒性和抗体产生[2]。

Odulimomab (1.5 和 0.75 mg/kg；腹腔注射，第 1 次治疗 1.5 mg/kg，然后每天注射 0.75 mg/kg) 对缺血和再灌注损伤有保护作用，对移植后肾功能有所修复[1]。 Animal Model: Cynomolgus Monkeys with renal damage ischemia and kidney autotransplantation[1] Dosage: 1.5 and 0.75 mg/kg Administration: Intraperitoneal injection; 1.5 mg/kg for the first dose and after pedicle clamping followed by daily injection of 0.75 mg/kg until sacrifice Result: Decreased the creatinine level after ischemia and autotransplantation for 3 days and increased the potassium fraction reabsorption.

[1]. Martin X, et al. Protective effect of an anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation. Transplant Proc. 2000 Mar;32(2):481.  

[2]. M. Hourmant & J. P. Soulillou. Interest in an anti-LFA-1 monoclonal antibody in the prevention of reperfusion injury in kidney transplantation. Organ Allocation pp 215–223.